Fingolimod

Generic Name: Fingolimod

Brand Names: Gilenya, Tascenso, Fingolimod Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₃₃NO_₂

CAS Number: 162359-55-9

Unique Ingredient Identifier: 3QN8BYN5QF

Background: Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was a...

Indication: Fingolimod is indicated for the treatment of patients aged 10 and above with relapsing forms of multiple sclerosis, which may include clinically isolated syndrome, relapsing-remitting disease, as well as active secondary progressive disease.

Associated Conditions: Relapsing Multiple Sclerosis (RMS)

Associated Therapies: Alternative Treatment

Clinical Trials

Revascularization Pretreated With Fingolimod in Acute Stroke

Not Applicable

Conditions: Stroke

Interventions: Drug: placebo
Drug: Fingolimod

First Posted Date: 2021-01-22

Last Posted Date: 2021-01-22

Lead Sponsor: The Affiliated Hospital of Xuzhou Medical University

Target Recruit Count: 20

Registration Number: NCT04718064

Relationship Between Oral DMT Burden and Adherence in MS

Conditions: Multiple Sclerosis
Adherence, Medication

Interventions: Drug: Cladribine
Drug: Fingolimod
Drug: Ozanimod
Drug: Dimethyl fumarate
Drug: Teriflunomide
Drug: Diroximel fumarate

First Posted Date: 2020-12-19

Last Posted Date: 2022-08-31

Lead Sponsor: Monash University

Target Recruit Count: 323

Registration Number: NCT04676204

Locations: 🇦🇺
Monash University, Melbourne, Victoria, Australia

Combinating Fingolimod With Alteplase Bridging With Thrombectomy in Acute Ischemic Stroke

Phase 2

Recruiting

Conditions: Stroke
Inflammation

Interventions: Other: Placebo
Drug: Fingolimod

First Posted Date: 2020-12-19

Last Posted Date: 2023-04-18

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 118

Registration Number: NCT04675762

Locations: 🇨🇳
The second affiliated hospital of Zhejiang University, Hangzhou, Zhejiang, China

Fingolimod in Endovascular Treatment of Ischemic Stroke

Phase 2

Conditions: Stroke Inflammation

Interventions: Drug: Fingolimod

First Posted Date: 2020-11-16

Last Posted Date: 2022-04-13

Lead Sponsor: Ning Wang, MD., PhD.

Target Recruit Count: 30

Registration Number: NCT04629872

Locations: 🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, China

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

Phase 4

Recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Fingolimod

First Posted Date: 2020-07-21

Last Posted Date: 2024-11-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT04480853

Locations: 🇨🇳
Novartis Investigative Site, Taoyuan, Taiwan

Fingolimod in Treating Patients With Chemotherapy-Induced Neuropathy

Early Phase 1

Completed

Conditions: Numbness
Pain
Chemotherapy-Induced Peripheral Neuropathy
Tingling

Interventions: Drug: Fingolimod
Drug: Fingolimod Hydrochloride
Other: Questionnaire Administration

First Posted Date: 2019-05-09

Last Posted Date: 2023-09-11

Lead Sponsor: Mayo Clinic

Target Recruit Count: 2

Registration Number: NCT03943498

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
The Ohio State University, Columbus, Ohio, United States

Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer

Phase 1

Completed

Conditions: Breast Carcinoma

Interventions: Drug: Fingolimod
Drug: Fingolimod Hydrochloride
Other: Questionnaire Administration

First Posted Date: 2019-05-08

Last Posted Date: 2023-07-21

Lead Sponsor: Mayo Clinic

Target Recruit Count: 2

Registration Number: NCT03941743

Locations: 🇺🇸
Virginia Commonwealth University/ Massey Cancer Center, Richmond, Virginia, United States
🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis

Phase 4

Terminated

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: Fingolimod
Drug: Dimethyl Fumarate

First Posted Date: 2017-11-17

Last Posted Date: 2019-10-31

Lead Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Target Recruit Count: 55

Registration Number: NCT03345940

Locations: 🇮🇹
Fondazione IRCCS Istituto Neurologico C. Besta, Neuroimmunology Unit, Milan, Italy

A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

Phase 4

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Fingolimod

First Posted Date: 2017-08-22

Last Posted Date: 2021-10-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 382

Registration Number: NCT03257358

Locations: 🇺🇸
Novartis Investigative Site, Neenah, Wisconsin, United States

Combinating Fingolimod With Alteplase Bridging With Mechanical Thrombectomy in Acute Ischemic Stroke

Phase 2

Withdrawn

Conditions: Inflammation
Stroke

Interventions: Drug: Fingolimod

First Posted Date: 2016-11-06

Last Posted Date: 2021-07-22

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Registration Number: NCT02956200

Locations: 🇨🇳
The second affiliated hospital of Zhejiang University, Hangzhou, Zhejiang, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy